Review

Lipid Abnormalities in Persons Living With HIV Infection

David D. Waters, MD, and Priscilla Y. Hsue, MD

Division of Cardiology, Zuckerberg San Francisco General Hospital, and Department of Medicine, University of California, San Francisco, California, USA

ABSTRACT

Lipid abnormalities are prevalent among persons living with HIV infection and contribute to increasing the risk of cardiovascular events. Antiretroviral therapy (ART) is associated with lipid abnormalities, most commonly hypertriglyceridemia, but also increases in low-density lipoprotein cholesterol and total cholesterol. Different classes of ART, and different drugs within classes, have differing effects on lipid levels, but in general newer drugs have more favorable effects compared with older ones. Low-level inflammation and chronic immune activation act on lipids through a variety of mechanisms to make them more atherogenic. As a consequence, risk is higher than would be expected for any given cholesterol level. Clinical outcome trials of cholesterol-lowering therapies have not yet been completed in people living with HIV, so that treatment decisions depend on extrapolation from studies in uninfected populations. Traditional risk assessment tools underestimate cardiovascular risk in individuals with HIV. Statins are the mainstay of lipid-lowering drug treatment; however, drug–drug interactions with ART must be considered. Simvastatin and lovastatin have a higher prevalence of rupture-prone coronary plaques compared with “ordinary” atherosclerosis.

The primary goals of this review are: (1) to describe the lipid abnormalities associated with HIV; (2) to summarize how lipoproteins might be influenced by HIV-associated inflammation; (3) to discuss treatment of lipid abnormalities in individuals with HIV; and (4) to summarize important features of other CV risk factors in people living with HIV.

Lipid Abnormalities

The onset of HIV infection was associated in one study with a decrease in total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), by a mean of 0.78, 0.57, and 0.31 mmol/L, respectively. In a study that compared HIV-infected with uninfected controls matched for age, sex, and body mass index, the HIV patients had lower HDL-C and LDL-C levels, and higher triglyceride, C-reactive protein (CRP), and interleukin (IL)-6 levels. Initiation of ART is recommended nowadays at the time of HIV diagnosis, so that the lipid abnormalities of untreated HIV patients are now limited to individuals in resource-limited countries for whom treatment is unavailable.

Corresponding author: Dr David D. Waters, Division of Cardiology, Room 5G1, Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, San Francisco, California 94110, USA. Tel.: +1-415-420-6646.
E-mail: David.Waters@ucsf.edu
See page 256 for disclosure information.

Received for publication August 23, 2018. Accepted November 6, 2018.

Canadian Journal of Cardiology 35 (2019) 249–259

https://doi.org/10.1016/j.cjca.2018.11.005
0828-282X/ © 2018 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
are contraindicated in patients taking protease inhibitors, and the dose of atorvastatin and rosvuastatin should be limited to 40 mg and 10 mg/d with some ART combinations. Switching from older forms of ART to lipid-friendly newer ones is a useful strategy as long as virologic suppression is maintained, but adding a statin lowers low-density lipoprotein cholesterol more effectively. Studies indicate that lipid abnormalities are not treated as aggressively in individuals living with HIV as they are in uninfected people, making this an opportunity to improve care.

The effect of ART on lipid levels varies a great deal among the classes of ART drugs, and even among drugs within the same class. The effects of specific ART drugs are often difficult to ascertain because HIV treatment requires multidrug therapy to limit replication of the virus through multiple mechanisms, as depicted in Figure 1.7 HIV drugs approved by the US Food and Drug Administration according to class are listed in Table 1, and combinations in Table 2. In general, PIs, non-nucleoside reverse transcriptase inhibitors (NNRTIs), and nucleoside reverse transcriptase inhibitor analogues (NRTIs) all increase triglyceride levels and might adversely affect LDL-C levels.

With initiation of older PIs, LDL-C and triglyceride levels increase, as do glucose and insulin levels.16 The increase in cholesterol levels with PIs is thought to be caused by increased cholesterol absorption rather than increased synthesis.15 Increases in LDL-C and triglyceride levels are higher with dual than with single PI therapy. Important differences have been described among PIs; in a report from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study, ritonavir and ritonavir-containing regimens increased triglyceride and LDL-C levels more, whereas saquinavir caused less abnormally low HDL-C levels, and nelfinavir was associated with fewer patients with high total cholesterol: HDL-C ratio.12 Interestingly, even after adjustment for lipid levels, cumulative exposure to lopinavir-ritonavir, indinavir, and didanosine were associated with increased risk of myocardial infarction (MI).13

In another study, the mean increase in LDL-C with initiation of a PI was 2.0 mmol/L with ritonavir, 0.8 mmol/L with indinavir, and 1.2 mmol/L with nelfinavir.14 Ritonavir, but not indinavir or nelfinavir, was associated with markedly elevated plasma triglyceride levels.15 Compared with older PIs, atazanavir and darunavir have more favourable lipid profiles.15

In clinical practice ritonavir might sometimes cause extreme hypertriglyceridemia with levels greater than 10 mmol/L and the risk of pancreatitis.16 Nowadays lower doses of ritonavir are usually used, with correspondingly less hypertriglyceridemia; however, increased triglyceride levels are also seen with combinations of ritonavir-saquinavir and ritonavir-lopinavir.16

NNRTIs also increase LDL-C levels, but do not depress HDL-C levels.12 Among NNRTIs, efavirenz was associated with slightly more patients developing hypercholesterolemia and hypertriglyceridemia compared with nevirapine.12 Efavirenz has been associated with greater increases in total and LDL-C but not total:HDL-C ratio compared with atazanavir-ritonavir.17 Compared with rilpivirine (another NNRTI), efavirenz is associated with higher total, HDL-C, LDL-C, and triglyceride levels.18 The NNRTI tenofovir alafenamide, a newer formulation of tenofovir disoproxil fumarate (TDF), is associated with higher levels of LDL-C and HDL-C, but similar total cholesterol:HDL-C ratios compared with tenofovir disoproxil fumarate.9 Overall, the prevalence of hyperlipidemia among people living with HIV across various studies ranges from 28% to 80%, with hypertriglyceridemia being the most common abnormality.19 This wide range is understandable, because of intrinsic differences in study populations and the evolution of HIV drug treatments. Hypertriglyceridemia in HIV patients has been related to their higher intake of total fat, saturated fat, trans fat, and cholesterol compared with HIV-negative controls.20 Saturated fat intake was strongly correlated with triglyceride levels, suggesting that increased saturated fat intake could be targeted for dietary modification in HIV patients.

Second-generation PIs such as atazanavir, the integrase inhibitors, and the C-C chemokine receptor type 5 coreceptor antagonist maraviroc have favourable effects on lipids, particularly compared with older forms of ART, as shown in Table 3.21 Lipid changes with 2 different integrase inhibitors, dolutegravir and raltegravir, appear to be similar.22 Most of the studies documenting these effects compared the newer agents with standard ART, or against placebo on a background of standard ART. In practice, suppression of HIV requires combination therapy, usually with 3-4 drugs. The effects of several of the most commonly used combinations on total cholesterol, LDL-C, HDL-C, triglycerides, and total:HDL-C ratio are illustrated in Figure 2.

Improvements in surrogate markers of atherosclerosis such as flow-mediated vasodilation and carotid intima-media thickness have been reported with newer ART drugs.21 Interestingly, in one study carotid intima-media thickness progression was less among participants who initiated atazanavir treatment.23 This benefit was attributed to atazanavir-related increases in bilirubin levels. Higher bilirubin levels, even within the normal range, appear to protect against...
atherosclerosis in Gilbert syndrome, and were associated with a lower risk of incident cardiovascular disease in individuals with and without HIV in the Veterans Aging Cohort Study. However, incident events in this study did not appear to be related to atazanavir use, and the mechanism by which atazanavir yields benefit, or even whether it does, remains controversial.

Most of the studies described in this section were of relatively short duration and were usually carried out in North American or European populations. However, ART is now begun most often in people living in sub-Saharan Africa, where fewer data are available on the metabolic effects of treatment. In a recent meta-analysis of 14 trials of 21,023 individuals assessed between 2003 and 2014 from this region, ART was associated with an increased risk of hypertriglyceridemia (relative risk, 2.05; 95% confidence interval [CI], 1.51-2.77). The associations between ART and raised blood pressure, glucose, hemoglobin A1c, and other lipids were inconsistent across studies.

The use of newer drugs with fewer adverse metabolic consequences might lead to a reduction in CV events among patients living with HIV. Initiation of ART in the earliest stages of HIV infection, as is now recommended, reduces inflammation, preserves immunologic function, and might be expected to reduce the potential of HIV infection to induce atherosclerosis.

**Interaction Between Inflammation and Lipoproteins in HIV**

In individuals without HIV infection, increased levels of LDL-C promote cholesterol accumulation and inflammation in the arterial wall. LDL-C within the vessel wall becomes oxidized and triggers proinflammatory pathways. Modified LDL-C is engulfed by macrophages, which increases toll-like receptor activity and leads to increased production of cytokines and chemokines. Counter-regulatory mechanisms oppose these changes. Cellular cholesterol accumulation activates adenosine triphosphate (ATP)-binding cassette transporters, which promote the efflux of cholesterol onto HDL-C or apolipoprotein A1, so that cholesterol is transported back to the liver for excretion.

Acute infections, or lipopolysaccharide administration in animals, interfere with reverse cholesterol transport at multiple points. HDL-C, which usually is an anti-inflammatory lipoprotein that suppresses monocyte adhesion to the endothelium, becomes proinflammatory and loses its protective effect against monocyte adhesion. The antioxidative properties of HDL-C are also impaired because of a loss of antioxidant proteins and accumulation of oxidized phospholipids. Macrophage myeloperoxidase, which is induced by inflammatory stimuli in atherosclerotic plaques, also mediates reductions in HDL-C function via oxidation.
Many of these mechanisms might be further enhanced because of their involvement in the pathogenesis of HIV infection. The gut is the portal of entry for HIV and macrophages. Because of microbial translocation, plasma levels of lipopolysaccharide and other microbial products, are increased in HIV-infected people. Lipopolysaccharide reduces ATP-binding cassette transporter activity, HDL-C function, and oxidized lipoproteins are associated with atherosclerosis in HIV. Markers of chronic inflammation and immune activation remain elevated in the setting of effectively treated HIV infection and are strongly predictive of mortality and CV events. Thus, aggressive treatment of lipids and HIV infection, and likely chronic inflammation as well, appear to be a reasonable approach to reduce the risk of CV events in this population.

### Treating Lipids in HIV Patients

Diet and lifestyle optimization should form the foundation for treatment of lipids in persons living with HIV. As with all overweight individuals, caloric restriction and exercise should be used to attain ideal body weight. Reducing carbohydrate intake can have a favourable effect on triglyceride levels. In one report, fasting triglyceride levels and adipose tissue mass decreased, and muscle mass increased in HIV-infected men with hypertriglyceridemia after 16 weeks of resistance training. Nevertheless, diet and exercise are by themselves rarely sufficient treatment.

A large number of controlled clinical trials have documented that LDL-C-lowering, usually with statins, reduces the risk of CV events across a broad spectrum of patients without HIV infection. Similar data are not available for people living with HIV; however, the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE), launched in 2015, will address this issue. In this trial 6500 HIV-infected participants without known CV disease will be randomized to pitavastatin 4 mg/d or to placebo with a planned average follow-up of 4 years. The primary end point of REPRIEVE will be a composite of CV mortality, MI, stroke or transient ischemic attack, unstable angina, peripheral artery disease, and arterial revascularization.

As previously noted, coronary lesions in persons living with HIV are more likely to be noncalcified, and thus prone to rupture compared with lesions in uninfected individuals. Even after adjustment for coronary risk factors, coronary artery plaque, especially noncalcified plaque, is more prevalent and extensive in HIV-infected men compared with controls. In a meta-analysis of 9 studies with 1229 persons with HIV and 1029 controls, noncalcified coronary plaques were much more

### Table 1. Antiretroviral therapy

| Class | Generic name | Abbreviation | Brand name | FDA approval |
|-------|--------------|--------------|------------|--------------|
| PI    | Atazanavir   | ATV          | Reyataz    | 2003         |
| PI    | Darunavir    | DRV          | Prezista   | 2006         |
| PI    | Fosamprenavir| FOS-APV, FPV | Lexiva      | 2003         |
| PI    | Ritonavir    | RTV          | Norvir     | 1996         |
| PI    | Saquinavir   | SQV          | Invirase   | 1995         |
| PI    | Tipranavir   | TPV          | Aptivus    | 2005         |
| NRTI  | Abacavir     | ABC          | Ziaqen     | 1998         |
| NRTI  | Emtricitabine| FTC          | Emtriva    | 2003         |
| NRTI  | Lamivudine   | STC          | Epivir     | 1995         |
| NRTI  | Tenofovir    | TDF          | Viread     | 2001         |
| NRTI  | Zidovudine   | AZT          | Retrovir   | 1987         |
| NNRTI | Doravirine   | DOR          | Pifeltro   | 2018         |
| NNRTI | Efavirenz    | EEF          | Sustiva    | 1998         |
| NNRTI | Etiravirine  | ETR          | Intelenze  | 2008         |
| NNRTI | Nevirapine   | NVP          | Viramune   | 1996         |
| NNRTI | Rilpivirine  | RPV          | Edurant    | 2011         |
| CCR5 anag | Maraviroc   | MVC          | Selzentry  | 2007         |
| II    | Dolutegravir | DTG          | Tivicay    | 2013         |
| II    | Raltegravir  | RAL          | Isentrest  | 2007         |
| FI    | Enfuvirtide  | T-20         | Fuzeon     | 2003         |
| PE    | Cobicistat   | COBI         | Tyobost    | 2014         |
| PPI   | Ib/zumab     | IBA          | Trogarzo   | 2018         |

antag, antagonist; CCR5, C-C chemokine receptor type 5; FDA, US Food and Drug Administration; FI, fusion inhibitor; II, integrase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PPI, postattachment inhibitor; PE, pharmacokinetic enhancer; PI, protease inhibitor.

*Although ritonavir is a PI it is generally used as a pharmacokinetic enhancer.

Data from the US Department of Health and Human Services.
common in HIV patients: 58% vs 17%, respectively (odds ratio, 3.26; 95% CI, 1.30-8.18). Fifty-eight percent vs 17% respectively (odds ratio, 3.26; 95% CI, 1.30-8.18)

Evidence from a small, randomized, placebo-controlled trial indicates that these lesions respond favourably to statins. Forty individuals with HIV, evidence of arterial inflammation in the aorta using FDG-PET, and LDL-C levels < 3.37 mmol/L were randomized to 1 year of treatment with atorvastatin or placebo. Atorvastatin reduced noncalciﬁed coronary plaque volume relative to placebo with a median reduction of 19.4% compared with an increase of 20.4% in the placebo group (P = 0.009). No difference between the groups was shown for aortic FDG-PET uptake, but this could only be evaluated in 21 of the 40 subjects.

Several lines of argument suggest that individuals living with HIV should use statins to reduce the risk of CV events. The risk of CV events in HIV-infected individuals is approximately double the risk in uninfected individuals, an increase in risk similar to what is seen with diabetes or hypertension. Statins have anti-inﬂammatory and LDL−C−lowering properties, a combination that might be particularly effective in breaking the cycle of inﬂammation and atherogenic lipoproteins described in the previous section. The effect of atorvastatin on noncalciﬁed plaques in HIV patients in the just-described trial is impressive, although the sample size of the trial was small. In a recent review and meta-analysis, statin treatment was reported to effectively reduce total, LDL-C, and non−HDLC, with a small increase in HDL-C and no significant change in triglycerides among individuals with HIV. Despite the LDL−C-lowering effect of statins, their lowering in inﬂammatory marker levels such as CRP and IL-6 are less pronounced than the response seen in uninfected persons. In the absence of outcomes data from large clinical trials, it might be worth noting that a meta-analysis of more than 35,000 individuals living with HIV showed that statin use was associated with a 33% reduction in all-cause mortality. Finally, it has been suggested on the basis of observational data that statins, presumably because of their anti-inﬂammatory effect, might reduce the incidence of malignancies in people with HIV.

With the exception of the 2016 European Society of Cardiology/European Atherosclerosis Society guidelines, cholesterol guidelines do not address management of persons living with HIV. The European Society of Cardiology/European Atherosclerosis Society guidelines recommend dietary changes and exercise, as well as switching, when feasible, to more lipid-friendly ART. The guidelines also state that statins should be considered to achieve the target LDL-C level for high-risk patients, namely 2.8 mmol/L. As in subjects without HIV infection, underlying causes of dyslipidemia such as hypothyroidism should be ruled out.

The 2013 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines recommend consideration of cholesterol-lowering treatment for individuals 40-79 years old with an LDL-C level of 1.8-5.0 mmol/L and a 10-year risk for a CV event of 7.5% or higher. Unfortunately,
the usual risk assessment tools are inaccurate in the setting of HIV. For example, in one recent study, high-risk coronary plaque morphology was seen on computed tomography angiography in 36% of 108 HIV patients, but the 2013 ACC/AHA guidelines would recommend statins for only 19% of them. Similarly, in another study the guidelines fail to recommend statin therapy for two-thirds of individuals with HIV who had carotid plaque on ultrasound imaging.

CV risk prediction using either Framingham or the 2013 ACC/AHA risk calculators systematically underestimates risk in HIV. Risk assessment tools have been designed specifically for HIV populations. One of them is on the basis of 1010 CV events that occurred in 32,663 HIV-positive persons from 20 countries in Europe, and Australia. The detailed model includes age, sex, systolic blood pressure, smoking status, family history of CV disease, diabetes, total cholesterol, HDL-C, CD4 lymphocyte count, cumulative exposure to PIs and NRTIs, and current use of abacavir. A reduced model excluded ART and current use of abacavir. The model performed better than the Framingham Risk Score even after the Framingham Risk Score had been recalibrated to the HIV population.

The 2018 AHA/ACC guidelines have recently been published. They mention HIV as a “risk enhancer” and make 3 recommendations for adults with chronic inflammatory disorders or HIV: (1) that these risk enhancers favour opting for moderate or high-intensity statin therapy in a discussion of risk; (2) that a risk assessment, including fasting lipid profile, be done before and 4-12 weeks after starting ART; and (3) for adults with rheumatoid arthritis, that risk assessment be repeated 2-4 months after the inflammatory disease has been controlled.

Drug—drug interactions must be considered when initiating lipid-lowering drugs in persons living with HIV. Table 4 summarizes the hepatic metabolic pathways and ART interactions for each of the 7 statins. A systemic review of 18 clinical trials in HIV-infected patients receiving ART confirmed that statin administration is safe when drug—drug interactions are accounted for. Simvastatin and lovastatin are contraindicated with PIs because of the risk of rhabdomyolysis from high statin blood levels. Similarly, no more than 40 mg/d of atorvastatin should be used for individuals taking ritonavir-boosted PIs. Rosuvastatin blood levels are increased when used with atazanavir/ritonavir and lopinavir/ritonavir, so limiting the rosuvastatin dose to 10 mg is advised with these drugs. Pravastatin and fluvastatin are safe but do not lower LDL-C as much as atorvastatin or rosuvastatin. These weaker statins were widely used after the introduction of ART, but are less popular now because of the growing realization, reflected in contemporary guidelines, that greater degrees of LDL-C-lowering produce greater CV event reduction.

Although not available in Canada, pitavastatin is theoretically a good choice for individuals living with HIV, because at higher doses its LDL-C-lowering effect is moderate, and because its metabolism is via glucuronidation, drug—drug interactions are avoided. In a randomized, double-blind comparison study in 252 subjects with HIV, pitavastatin 4 mg/d reduced LDL-C by 31% and pravastatin 40 mg/d reduced LDL-C by 21%, with similar low rates of adverse events in the 2 treatment groups. Levels of soluble CD14, oxidized LDL-C, and lipoprotein-associated phospholipase 2 were significantly lower in the pitavastatin group compared with the pravastatin group.

As with other patients, statins should be the mainstay of lipid-lowering drug therapy for persons living with HIV. Several studies indicate that statins are underused in the setting of HIV.

Figure 2. Effects of common combinations of antiretroviral therapy on lipid levels. HDL, high-density lipoprotein; LDL, low-density lipoprotein. Reproduced from Lake and Currier from The Lancet with permission from Elsevier.
In individuals living with HIV who do not tolerate statins, ezetimibe is a safe option, albeit with limited LDL-C-lowering efficacy. Ezetimibe could be considered as add-on therapy for very high-risk individuals with HIV who do not achieve satisfactory LDL-C lowering with statins. Bile acid sequestrants are not recommended in HIV-infected individuals because they increase triglyceride levels and their effects on the absorption of antiretroviral drugs have not been studied. Add-on therapy can be problematic for individuals with HIV because they often already suffer from a high pill burden because of ART and other medications.

We have reported high proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in the setting of HIV, and are currently investigating PCSK9 inhibitors in a randomized, placebo-controlled trial as a potential treatment to reduce CV risk using multimodality assessment of coronary plaque, arterial inflammation, and endothelial function for individuals with HIV. PCSK9 inhibitors have inherent advantages in this circumstance, including profound LDL-C-lowering, a reduction in pill burden, avoidance of the drug–drug interactions of statins, and ease of use in patients with chronic liver disease, a common problem in this population.

Switching ART to drugs that do not adversely affect lipid levels is a worthwhile strategy as long as viral suppression is maintained. Switching from older PIs to integrase inhibitors has been shown to improve lipid levels, but at the cost of an increased risk of virologic failure, and thus is not recommended for individuals with this history. In another study of 415 subjects with HIV and high CV risk, half were randomized to continue a ritonavir-boosted PI regimen and half were switched to dolutegravir, an integrase inhibitor. After 48 weeks, no difference between the treatment groups was seen for virologic failure, but total cholesterol, LDL-C, and triglyceride levels all improved ($P < 0.0001$) in the dolutegravir group. Additional use of a statin might be preferable to switching for those not already taking a statin; in one study the additional use of rosvastatin 10 mg/d yielded better lipid results and was better tolerated compared with switching.

Hypertriglyceridemia is a common finding in individuals with HIV and might be related to ART or HIV itself. Reducing alcohol and carbohydrate intake has a favourable effect in persons with or without HIV infection. Consideration should be given to a change in ART to drugs that induce less hypertriglyceridemia. Fibrates reduce triglycerides, often at low doses, but have a drug–drug interaction with statins and some types of ART; for example, the lopinavir-ritonavir PI combination greatly reduces gemfibrozil absorption. Monitoring of hepatic enzymes and creatine phosphokinase levels is advised for patients taking ART, a statin, and a fibrate. Fish oil has been shown to reduce triglyceride levels in persons with HIV and hypertriglyceridemia, and has the advantage of no important drug–drug interactions; however, fish oil does increase LDL-C levels modestly. When triglycerides exceed 10 mmol/L, pancreatitis is a serious risk; lower levels of hypertriglyceridemia probably increase CV risk. If pancreatitis does develop, the offending drug must be withdrawn and supportive care instituted.

The recently published Reduction of Cardiovascular Events with Icosapent Ethyl Intervention Trial (REDUCE-IT) tested the effect of icosapent ethyl, a stable eicosapentaenoic acid ethyl ester, as add-on therapy with statins in 8179 patients with CV disease or diabetes and other CV risk factors, and a fasting triglyceride level of 1.69–5.63 mmol/L (150–499 mg/dL). Although outcome data such as this are not available for hypertriglyceridemic individuals living with HIV, icosapent ethyl should now be considered as treatment for such persons.

Inflammation is a potential therapeutic target for a reduction of CV events, in persons with and without HIV infection. Canakinumab, a monoclonal antibody targeting IL-1β, was recently evaluated in a randomized, placebo-controlled trial of 10,061 patients with previous MI and a CRP level of ≥ 2 mg/L. The 3 doses of canakinumab that were tested all reduced CRP, from 26% to 41%, but did not affect LDL-C levels. At the intermediate and higher doses, canakinumab reduced the primary composite end point of CV death, MI, and stroke. Patients who had a CRP reduction to < 2 mg/L experienced significant reductions in CV events, coronary heart disease death, and all-cause mortality, whereas those without a CRP reduction to this level did not.

Would canakinumab reduce CV risk in HIV-infected subjects? Our group has shown that canakinumab significantly reduced IL-6 and CRP levels with no effect on CD4, CD8, RNA viral levels, or lipids in a small study of subjects with HIV infection. Another anti-inflammatory drug, methotrexate, has been associated with reductions in CV events among individuals with rheumatoid arthritis, an inflammatory condition with elevated markers of inflammation and elevated CV risk. The effect of low-dose methotrexate on CV events was studied in the recently published Cardiovascular Inflammation Reduction Trial (CIRT), in 4786 individuals with known CV disease or diabetes. The trial was
stopped after a median follow-up of 2.3 years. Compared with placebo, methotrexate did not lower levels of IL-1β, IL-6, or CRP, and had no effect on CV events.

Similarly, in a multicentre study, our group reported no effect of low-dose methotrexate on inflammatory markers or endothelial function but methotrexate did favourably affect coronary artery echogenicity, a surrogate marker of plaque composition. These preliminary studies with inflammatory biomarkers as surrogate endpoints will hopefully lead to larger trials of anti-inflammatory treatments with CV events as endpoints among individuals living with HIV.

**Unique Features of Other CV Risk Factors in HIV Patients**

Whether HIV infection is associated with an increased risk of diabetes has been controversial. PIs and thymidine analogues, specifically stavudine, can cause insulin resistance; however, these drugs are rarely used nowadays because of their toxicity. In a large cohort study from Denmark, the risk of diabetes among HIV-infected individuals was nearly 3 times higher than in the general population from 1996 to 1999, but this excess was no longer present from 1999 to 2010. However, in a recent cross-sectional study from sub-Saharan Africa, the prevalence of diabetes was higher in people living with HIV compared with uninfected controls, as was the prevalence of a glycated hemoglobin level of at least 6%. Lipodystrophy is a syndrome that results in central adiposity from accumulation of fat in the dorsocervical region, with increased or preserved visceral fat and peripheral fat loss.

Lipodystrophy develops in 20%-35% of patients taking PIs or the NRTIs didanosine or stavudine. Newer PIs such as atazanavir do not appear to cause lipodystrophy. Lipodystrophy in HIV is commonly associated with components of the metabolic syndrome: insulin resistance, impaired glucose tolerance, hypertriglyceridemia, low HDL-C levels, and hypertension. The insulin resistance associated with lipodystrophy can be severe, and might even precipitate diabetes. Reported rates of the metabolic syndrome in persons living with HIV range from 8.5% to 52%, with rates at the higher end of this range found in Latin American countries and rates at the lower end in multicentre studies in which patients had less exposure to ART.

Lipodystrophy commonly develops during the first 3 years after initiation of an ART regimen that includes lopinavir/ritonavir or stavudine. The metabolic syndrome is a predictor of CV events and death in HIV-infected individuals according to most studies. Hypertension and prehypertension have been shown to be risk factors for CV events in HIV-infected persons, just as they are for uninfected individuals. Similarly, chronic kidney disease), expressed as either albuminuric or a decreased glomerular filtration rate, is associated with an increased risk of CV events in HIV-infected patients. In a cohort of 35,357 persons with HIV, lower glomerular filtration rate was strongly associated with higher CV risk. The prevalence of hypertension and chronic kidney disease appears to be higher than normal in HIV-infected persons among individuals exposed to some forms of ART.

Smoking is highly prevalent among those infected with HIV. In a large cohort study from Denmark, nearly half of HIV patients were smokers compared with one-fifth of uninfected people. All-cause mortality rates were much higher among smokers compared with nonsmokers with HIV. For example, a 35-year-old person living with HIV had a median life expectancy of 62.6 years (95% CI, 59.9-64.6) if a smoker and 78.4 years (95% CI, 70.8-84.0) if a nonsmoker. Smoking caused more lost life-years than HIV, 12.3 vs 5.1. The population-attributable risk of death due to smoking was 61.5% in individuals with HIV and 34.2% among uninfected people.

Smoking cessation programs appear to have the same modest success rates in people with HIV as in uninfected individuals. In a meta-analysis of 8 trials including 1822 HIV-infected smokers, behavioural interventions increased abstinence rates by approximately half (relative risk, 1.51; 95% CI, 1.17-1.95). Training physicians who care for individuals living with HIV to provide smoking cessation counselling and treatment increased smoking cessation rates and decreased relapse rates in one study. Potential drug–drug interactions between ART and drugs for smoking cessation have not been well studied. Studies of varenicline, bupropion, and nicotine replacement therapy in persons with HIV have generally been small, short, and uncontrolled, but have shown safety and success rates similar to reports in uninfected subjects.

The effect of smoking cessation on the rates of subsequent CV events was reported for a large cohort in the D:A:D study. Among those who stopped smoking, the incidence of MI and other CV events began to decrease within the first year, with a further decrease thereafter. This pattern is similar to what is seen in quitters without HIV infection, making smoking cessation a very desirable therapeutic goal.

**Conclusion**

Persons living with HIV are now older and at increased risk for CV events. The presence of HIV approximately doubles CV risk, as does either diabetes or hypertension. Lipid abnormalities are common among individuals with HIV infection, and their lipids are abnormally atherogenic, because of several inter-related factors. Although clinical trial data with lipid-lowering drugs is not yet available for those with HIV, guidelines recommend that they be treated aggressively with statins. Simvastatin and lovastatin are contraindicated with PIs because of drug–drug interactions. Studies indicate that statins are underused in the setting of HIV, perhaps because HIV specialists might not have the expertise to manage CV risk, and because cardiologists do not have expertise in HIV or appreciation of CV risk in this unique population.

**Disclosures**

Dr Waters has received remuneration from pharmaceutical companies for participating in clinical trial committees of investigational cholesterol drugs. Dr Hsue has received honoraria from Gilead and Merck.

**References**

1. Shah AS, Stelzle D, Lee KK, et al. Global burden of atherosclerotic cardiovascular disease in people living with the human immunodeficiency virus: a systematic review and meta-analysis. Circulation 2018;138:1100-12.
2. Hsue PY, Waters DD. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation 2018;138:1113-5.
3. Lake JE, Currier JS. Metabolic disease in HIV infection. Lancet Infect Dis 2013;13:964-75.
4. Funderburg NT, Mehta NN. Lipid abnormalities and inflammation in HIV infection. Curr HIV/AIDS Rep 2016;13:218-25.
5. D’Ascenzo F, Cerrato E, Calcagno A, et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis 2015;240:197-204.
6. Riddler SA, Smir E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82.
7. Fourie CM, Van Rooyen JM, Kruger A, Schutte AE. Lipid abnormalities in a never-treated HIV-1 subtype C-infected African population. Lipids 2010;45:73-80.
8. Günthard HF, Saag MS, Benson CA, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults. 2016 Recommendations of the International Antiviral Society—USA Panel. JAMA 2016;316:191-210.
9. Smith RL, de Boer R, Brul S, Budovskaya Y, van Spek. Premature and accelerated aging; HIV or HAART? Front Genet 2012;3:328.
10. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
11. Leyes P, Cofan M, González-Cordón A, et al. Increased cholesterol absorption rather than synthesis is involved in boosted protease inhibitor-associated hypercholesterolaemia. AIDS 2018;32:1309-16.
12. Fontas E, van Leth F, Sahin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different drugs associated with different lipid profiles? J Infect Dis 2004;189:1056-74.
13. Worm SW, Sahin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010;201:318-30.
14. Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700-5.
15. UcciFerri C, Falasca K, Vignale F, et al. Improved metabolic profile after switch to darunavir/ritonavir in HIV positive patients previously on protease inhibitor therapy. J Med Virol 2013;85:755-9.
16. Hse PY, Waters DD. Cardiovascular abnormalities in HIV-infected individuals. In: Zipes DP, Libby P, Bonow RO, Mann DL, Tomaselli GF, eds. Braunwald’s Heart Disease. A textbook of cardiovascular medicine. 11th Ed. Elsevier, 2019:1651-61.
17. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2014;161:1-10.
18. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-46.
19. Sax PE, Zolopa A, Brar I, et al. Tenofovir alafenamide vs tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study. J Acquir Immune Defic Syndr 2014;67:52-8.
20. Joy T, Keogh HM, Hadigan C, et al. Dietary fat intake and relationship to serum lipid levels in HIV-infected patients with metabolic abnormalities in the HAART era. AIDS 2007;21:1591-600.
21. Srivinasa S, Grinspoon SK. Metabolic and body composition effects of newer antiretrovirals in HIV-infected patients. Eur J Endocrinol 2014;170:R185-202.
22. Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily doravirine versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013;381:735-43.
23. Stein JH, Ribaudo HJ, Hodis HN, et al. A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS 2015;29:1775-83.
24. Vitek L, Jirsa M Jr, Bradanova M, et al. Gilbert syndrome and ischemic heart disease: a protective effect of elevated bilirubin levels. Atherosclerosis 2002;160:449-56.
25. Marconi VC, Duncan MS, So-Armah K, et al. Bilirubin is inversely associated with cardiovascular disease among HIV-positive and HIV-negative individuals in VACS (Veterans Aging Cohort Study). J Am Heart Assoc 2018;7:e007792.
26. Ekoru K, Young EH, Dillon DG, et al. HIV treatment is associated with a two-fold higher probability of raised triglycerides: Pooled Analyses in 21 023 individuals in sub-Saharan Africa. Glob Health Epidemiol Genom 2018;3:e7.
27. Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol 2015;15:104-16.
28. Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-71.
29. McGillicuddy FC, de la Llera Moya M, Hinkle CC, et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation 2009;119:1135-45.
30. Maisa A, Hearps AC, Angelovich TA, et al. Monocytes from HIV-infected individuals show impaired cholesterol efflux and increased foam cell formation after transendothelial migration. AIDS 2015;29:1445-57.
31. Sandler NG, Wand H, Roque A, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis 2011;203:780-90.
32. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011;204:1227-36.
33. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012;25;308:379-86.
34. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 2014;371:2383-93.
35. Mungar AM, Chow DC, Playford MP, et al. Characterization of lipid composition and high-density lipoprotein function in HIV-infected individuals on stable antiretroviral regimens. AIDS Res Hum Retroviruses 2015;31:221-8.
36. Zidar DA, Juchnowski S, Ferrari B, et al. Oxidized LDL levels are increased in HIV infection and may drive monocyte activation. J Acquir Immune Defic Syndr 2015;69:154-60.
37. Kelesidis T, Jackson N, McComsey GA, et al. Oxidized lipoproteins are associated with markers of inflammation and immune activation in HIV-1 infection. AIDS 2016;30:2625-33.
38. Parra S, Coll B, Aragonés G, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010;11:225-31.

39. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788-95.

40. Grund B, Baker JV, Deeks SG, et al. Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One 2016;11:e0155100.

41. Oh J, Hegele R. HIV-associated dyslipidaemia: pathogenesis and treatment. Lancet Infect Dis 2007;7:787-96.

42. Yarasheski KE, Tebas P, Stanerson B, et al. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiretroviral therapy. J Appl Physiol 2001;90:133-8.

43. Henry K, Melroe H, Huebesch J, Hermundson J, Simpson J. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities. Lancet 1998;352:1031-2.

44. Gilbert JM, Fitch KV, Grinspoon SK. HIV-related cardiovascular disease, statins, and the REPRIEvE trial. Top Antivir Med 2015;23:146-9.

45. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014;160:458-67.

46. Lo J, Lu MT, Ihenachor EJ, et al. Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial. Lancet HIV 2015;2:e52-63.

47. Banach M, Dinca M, Ursoniu S, et al. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacol Res 2016;111:343-56.

48. Eckard AR, Jiang Y, Debanne SM, et al. Effect of 24 weeks of statin therapy. J Appl Physiol 2001;90:133-8.

49. Uthman OA, Nduku C, Watson SI, et al. Statin use and all-cause mortality in people living with HIV: a systematic review and meta-analysis. BMC Infect Dis 2018;18:258.

50. Overton ET, Kitch D, Benson CA, et al. Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin Infect Dis 2013;56:1471-9.

51. Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016;37:2999-3058.

52. Zannì MV, Fitch KV, Feldpausch M, et al. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS 2014;28:2061-70.

53. Phan BA, Weigl B, Ma Y, et al. Utility of 2013 American College of Cardiology/American Heart Association cholesterol guidelines in HIV-infected adults with carotid atherosclerosis. Circ Cardiovasc Imaging 2017;10:e005995.

54. Friis-Møller N, Ryom L, Smith C, et al. An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study. Eur J Prev Cardiol 2016;23:214-23.

55. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPNC/PCNA Guideline on the management of blood cholesterol: executive summary [e-pub ahead of print]. J Am Coll Cardiol, https://doi.org/10.1016/j.jacc.2018.11.002. Accessed December 22, 2018.

56. Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. Am J Cardiol 2015;115:1760-6.

57. Busti AJ, Bain AM, Hall RG 2nd, et al. Effects of atazanavir/ritonavir or fosamprenavir/ritonavir on the pharmacokinetics of rosuvastatin. J Cardiovasc Pharmacol 2008;51:605-10.

58. Waters DD, Boekholt SM. An evidence-based guide to cholesterol-lowering guidelines. Can J Cardiol 2017;33:343-9.

59. Mosepele M, Molefe-Baikai OJ, Grinspoon SK, Triant VA. Benefits and risks of statin therapy in an HIV-infected population. Curr Infect Dis Rep 2018;20:20.

60. Aberg JA, Spenseller CA, Ward DJ, et al. Pitavastatin versus pravastatin in adults with HIV-1 infection and dyslipidaemia (INTREPID): 12 week and 52 week results of a phase 4, multicentre, randomised, double-blind, superiority trial. Lancet HIV 2017;4:e284-94.

61. Toribio M, Fitch KV, Sanchez L, et al. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS 2017;31:797-806.

62. Levy ME, Greenberg AE, Magnus M, Younes N, Castel A. Evaluation of statin eligibility, prescribing practices, and therapeutic responses using ATP III, ACC/AHA, and NLA dyslipidemia treatment guidelines in a large urban cohort of HIV-infected outpatients. AIDS Patient Care STDs 2018;32:58-69.

63. Ladapo JA, Richards AK, DeWitt CM, et al. Disparities in the quality of cardiovascular care between HIV-infected versus HIV-uninfected adults in the United States: a cross-sectional study. J Am Heart Assoc 2017;6:e007107.

64. Wohl DA, Waters D, Simpson RJ Jr, et al. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Clin Infect Dis 2008;47:1105-8.

65. Kohli P, Ganz P, Ma Y, et al. HIV and hepatitis C-coinfected patients have lower low-density lipoprotein cholesterol despite higher proprotein convertase subtilisin kexin 9 (PCSK9): an apparent “PCSK9-lipid paradox.” J Am Heart Assoc 2016;5:e002683.

66. ClinicalTrials.gov. Effect of PCSK9 Inhibition on Cardiovascular risk in treated HIV infection (EPIC-HIV study). Available at: https://clinicaltrials.gov/ct2/show/NCT03207945. Accessed July 27, 2018.

67. Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viremia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407.

68. Garrell JM, Assoumou L, Moyle G, et al. Switching from a ritonavir-boosted protease inhibitor to a dolasetravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk. AIDS 2017;31:2503-14.

69. Lee FJ, Monteiro P, Baker D, et al. Rosuvastatin vs. protease inhibitor switching for hypercholesterolaemia: a randomized trial. HIV Med 2016;17:605-14.
70. Busse KH, Hadigan C, Chaitra C, et al. Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir. J Acquir Immune Defic Syndr 2009;52:235-9.

71. Gerber JG, Kitch DW, Fichtenbaum CJ, et al. Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV infected subjects on antiretroviral therapy. Results of ACTG A5186. J Acquir Immune Defic Syndr 2008;47:459-66.

72. Muñoz MA, Liu W, Delaney JA, et al. Comparative effectiveness of fish oil versus fenofibrate, gemfibrozil, and atorvastatin on lowering triglyceride levels among HIV-infected patients in routine clinical care. J Acquir Immune Defic Syndr 2013;64:254-60.

73. Balani AR, Grendell JH. Drug-induced pancreatic: incidence, management and prevention. Drug Saf 2008;31:823-37.

74. Bhattacharya R, Seng G, Miller M, et al. Cardiovascular risk reduction with isosapent ethyl for hypertriglyceridemia. N Engl J Med 2019;380:11-22.

75. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017;377:1119-31.

76. Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet 2018;391:319-28.

77. Hsue PY, Li D, Ma Y, et al. IL-1β inhibition reduces atherosclerotic inflammation in HIV infection. J Am Coll Cardiol 2018;72:2809-11.

78. Micha R, Imamura F, Wyler von Ballmoos M, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. J Acquir Immune Defic Syndr https://doi.org/10.1093/NEJMoA1809798. Accessed December 22, 2018.

79. Rohde P, Chaitra C, Chaitra A, et al. Low-dose methotrexate for the prevention of atherosclerotic events [e-pub ahead of print]. N Engl J Med https://doi.org/10.1056/NEJMoA1809798. Accessed December 22, 2018.

80. Hsue PY, Ribaudo HJ, Deeks SG, et al. Safety and impact of low-dose methotrexate on endothelial function and inflammation in individuals with treated human immunodeficiency virus: AIDS Clinical Trial Group Study A5314 [e-pub ahead of print]. Clin Infect Dis https://doi.org/10.1093/cid/ciy781. Accessed December 22, 2018.

81. Stein JH, Yeh E, Weber JM, et al. Brachial artery echogenicity and grayscale texture changes in HIV-infected individuals receiving low-dose methotrexate: AIDS Clinical Trial Group Study. Arterioscler Thromb Vasc Biol 2018;38:2870-8.

82. Nix L, Tien PC. Metabolic syndrome, diabetes, and cardiovascular risk in HIV. Curr HIV/AIDS Rep 2014;11:271-8.